Sanofi teams with Innate Pharma in Deal to develop cancer drugs
Monday, January 11, 2016
Sanofi has teamed up with Innate Pharma SA in an effort to develop cancer treatments using the body’s own immune system.
Under the agreement, the drugmakers will develop up to two treatments, using antibodies to engage so-called natural-killer cells to attack tumors, according to a statement Sunday.
The agreement signals an ambition by Sanofi to capture a larger slice of the spending on cancer treatments, which has grown by 6.5 percent annually in the past five years and reached $100 billion in 2014, according to the IMS Institute for Healthcare Informatics. The U.S. and the five largest countries in Europe account for two-thirds of the total spending, the report said.
Paris-based Sanofi will lead development, manufacturing and marketing of any products. Innate, based in Marseille, could receive payments of as much 400 million euros ($437 million) as well as royalties on net sales.
bloomberg.com
